Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy

J. Planas Morin, A. Celma Domenech, J. Placer Santos, E. Trilla Herrera, C. Salvador Lacambra, D. Lorente Garcia, L. Regis, J. Carles Galceran, J. Morote Robles

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

© 2014, Springer-Verlag Berlin Heidelberg. The aim of this study was to evaluate bone mass changes after 1 year of four different types of pharmacological intervention. Ninety-seven prostate cancer patients treated with androgen deprivation therapy, and severe osteopenia or osteoporosis were retrospectively studied. Patients were divided in four groups. Group 1: 28 patients treated with denosumab, Group 2: 24 patients treated with alendronate, Group 3: 24 patients with no antiresorptive treatment and Group 4: 21 patients previously treated with alendronate and switched to denosumab. Dual X-ray absorptiometry was performed at baseline and after 1 year. Bone mass changes at the L2–L4 lumbar spine, femoral neck and total hip were evaluated. No differences were found at baseline. After 1 year, men receiving denosumab or alendronate (Group 1 and 2) showed a significant bone mass increase at the lumbar spine (+2.4 and +5.0 %, respectively), while no significant changes were observed in Group 3 and 4. At the femoral neck, Group 1 and 2 patients showed a significant bone mass increase (+3.7 and +3.6 %, respectively), while no significant changes were observed in Group 3 and 4. At the total hip, we observed a significant bone mass increase in Group 1 (+2.9 %) and a significant bone mass loss in Group 3 patients (−1.9 %). No significant changes were observed in Group 2 and 4. Denosumab increased significantly bone mass in all three dual X-ray absorptiometry standard sites, while alendronate did not at total hip. No benefit was observed in men previously treated with alendronate who switched to denosumab treatment.
Original languageEnglish
Pages (from-to)1419-1425
JournalRheumatology International
Volume34
Issue number10
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • Androgen deprivation therapy
  • Cancer treatment-induced bone loss
  • Osteoporosis
  • Prostate cancer

Fingerprint Dive into the research topics of 'Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy'. Together they form a unique fingerprint.

Cite this